FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/New Study Reveals Insights into GLP-1 Receptor Agonist’s Impact on Ingestive Behavior
연구 도서관으로 돌아가기

New Study Reveals Insights into GLP-1 Receptor Agonist’s Impact on Ingestive Behavior

May 25, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

New Study Reveals Insights into GLP-1 Receptor Agonist’s Impact on Ingestive Behavior

A new study underway at University College Dublin aims to uncover how semaglutide, a popular peptide therapy used for metabolic diseases and obesity management, affects eating patterns. The DIGRAT (Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment) trial is shedding light on the mechanisms behind reduced food intake when using this medication.

Background

Peptide therapies like semaglutide are widely recognized for their effectiveness in managing conditions such as type 2 diabetes and obesity. These treatments work by mimicking the action of GLP-1, a hormone that plays a critical role in regulating blood glucose levels and promoting satiety. However, the exact mechanisms through which these medications influence eating behaviors have not been fully explored until now.

The DIGRAT study aims to fill this knowledge gap by closely examining how semaglutide impacts food intake patterns at its maximum dose of 1 mg weekly injection. Understanding these effects is crucial for optimizing treatment strategies and improving patient outcomes.

Key Details

Launched in May 2026, the DIGRAT trial has been actively enrolling participants to study the microstructure of ingestive behavior after initiating GLP-1 receptor agonist therapy. Researchers are particularly interested in how semaglutide influences various aspects of eating, including frequency and duration of meals.

The study’s primary objective is to measure changes in these behaviors over time using advanced monitoring techniques. By doing so, investigators hope to provide a clearer picture of how semaglutide impacts the digestive system and brain pathways involved in appetite regulation.

Key Takeaways

  • Enhanced Understanding: The DIGRAT trial provides valuable insights into how GLP-1 receptor agonists alter eating patterns.
  • Mechanistic Clues: Researchers are identifying specific changes in meal frequency and duration linked to semaglutide use.
  • Optimized Treatment: These findings could lead to more personalized approaches for managing metabolic diseases with peptide therapy.
  • Regulatory Impact: Such detailed mechanistic data can support future FDA regulations regarding the approval of similar therapies.

What This Means

For the peptide community, this research offers a deeper look into how GLP-1 receptor agonists work and their potential benefits beyond just blood sugar control. The insights gained from DIGRAT could pave the way for more targeted interventions in obesity management and diabetes care. As the understanding of these mechanisms grows, so too will our ability to tailor peptide therapies to individual patient needs.

---

Source: ClinicalTrials.gov — Published 2026-05-15

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.